How has competition affected keytruda's cost?

How does competition shape Keytruda pricing?

Merck’s Keytruda has held a dominant position in the checkpoint-inhibitor class since its launch, largely because few products cleared regulatory hurdles ahead of it. Early competition remained thin, so the company maintained list prices above $170,000 per year.

What happens when biosimilars arrive?

No approved Keytruda biosimilar exists yet. Developers continue to run large clinical programs, but current patents block any generic or biosimilar launch before 2028 at the earliest. Until then, Merck retains pricing power and can still raise the annual cost per patient several percent each year.

Why are companies challenging this patent?

Multiple firms filed Paragraph IV challenges against Keytruda’s key patents. Those disputes center on formulation claims and method-of-use patents that protect the melanoma and lung-cancer indications. Companies such as Celltrion and Samsung Bioepis continue litigation, but any win still requires regulatory approval and marketing launch.

How does Keytruda compare with Opdivo?

Opdivo (nivolumab) entered the checkpoint-inhibitor field shortly after Keytruda. Both drugs trade at similar list prices, but Opdivo’s sales remain lower than Keytruda’s. Merck’s broader label set keeps Keytruda’s pricing trajectory steadier than Opdivo’s.

When does exclusivity expire?

Keytruda’s basic compound patent expires in 2028. Extended market exclusivity through pediatric and orphan-drug protections pushes full generic entry later. DrugPatentWatch.com lists the full schedule of composition-of-matter and method-of-use patents that keep competitors out until then.